JP5032981B2 - メラトニン、および術後合併症の防止におけるその使用 - Google Patents
メラトニン、および術後合併症の防止におけるその使用 Download PDFInfo
- Publication number
- JP5032981B2 JP5032981B2 JP2007509957A JP2007509957A JP5032981B2 JP 5032981 B2 JP5032981 B2 JP 5032981B2 JP 2007509957 A JP2007509957 A JP 2007509957A JP 2007509957 A JP2007509957 A JP 2007509957A JP 5032981 B2 JP5032981 B2 JP 5032981B2
- Authority
- JP
- Japan
- Prior art keywords
- melatonin
- surgery
- complications
- pharmaceutical composition
- surgical intervention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 69
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960003987 melatonin Drugs 0.000 title claims abstract description 68
- 208000035965 Postoperative Complications Diseases 0.000 title claims description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 33
- 230000002458 infectious effect Effects 0.000 claims abstract description 28
- 238000011477 surgical intervention Methods 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 15
- 238000011321 prophylaxis Methods 0.000 claims abstract description 15
- 230000002980 postoperative effect Effects 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 7
- 206010050456 Anastomotic leak Diseases 0.000 claims abstract description 5
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 5
- 206010048038 Wound infection Diseases 0.000 claims abstract description 4
- 206010048031 Wound dehiscence Diseases 0.000 claims abstract description 3
- 206010060921 Abdominal abscess Diseases 0.000 claims abstract 2
- 238000001356 surgical procedure Methods 0.000 claims description 61
- 210000004185 liver Anatomy 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 208000028867 ischemia Diseases 0.000 claims description 16
- 210000002784 stomach Anatomy 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000002192 cholecystectomy Methods 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 238000010911 splenectomy Methods 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 20
- 150000001875 compounds Chemical class 0.000 abstract description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract description 14
- 229930064664 L-arginine Natural products 0.000 abstract description 14
- 235000014852 L-arginine Nutrition 0.000 abstract description 14
- 150000003839 salts Chemical class 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 description 21
- 238000009472 formulation Methods 0.000 description 16
- 230000010410 reperfusion Effects 0.000 description 12
- 210000005228 liver tissue Anatomy 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000012753 partial hepatectomy Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005162 left hepatic lobe Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000005163 right hepatic lobe Anatomy 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059118 Biloma Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034649 Peritoneal abscess Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000036064 Surgical Blood Loss Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010046411 Ureteric stenosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000031972 neutrophil apoptotic process Effects 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- -1 peroxynitrite anions Chemical class 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000007468 re-laparotomy Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
過度の出血を防止するために血管をクランプで締めることにより誘発される臓器および組織の虚血およびそれに続く再潅流は手術処置中に回避することができない。そのような標準の虚血/再潅流状況は、臨床的に適切なラット手術モデルにおける部分的肝切除によってシミュレーションすることができる。
4群の雌Sprague Dawleyラット(200〜220g)(1群につき10匹)に開腹手術を行い、その後20分間右側部肝葉のクランピングを行い、臓器全体の約30%に低酸素症を来した。虚血組織の再潅流後、残りの約70%の肝臓の非虚血中央および左側部肝葉を手術により除去し、手術による切開を閉鎖した。7日間の追跡調査中、虚血/再潅流の影響を肝傷害および生存に関して観察した。
Claims (8)
- 外科的介入によって誘発される、肺炎、創傷感染(創傷裂開)、腹腔内膿瘍、および尿路感染(UTI)からなる群から選択される術後感染性合併症および/または術後非感染性合併症である吻合部漏出の、予防的処置および/または防止のためのメラトニンを含む、虚血によって誘発される組織傷害を軽減または防止するための医薬組成物。
- メラトニンが外科的介入の前に投与される、請求項1に記載の医薬組成物。
- メラトニンが、術後合併症の予防的処置および/または防止を目的とした、唯一の治療的に有効な物質として使用される、請求項1又は2に記載の医薬組成物。
- 外科的介入がB型および/またはC型手術から選択される、請求項1〜3のいずれか一項に記載の医薬組成物。
- Bおよび/またはC型手術が胃、小腸および結腸手術、脾臓切除術、胆嚢切除術、肝臓手術、食道、すい臓、直腸、および後腹膜腔に対する手術から選択される、請求項4に記載の医薬組成物。
- 術後合併症の予防的処置および/または防止のために、外科的介入の24時間未満前に薬物が適用される、請求項1〜5のいずれか一項に記載の医薬組成物。
- 術後合併症の予防的処置および/または防止のために、外科的介入の3時間未満前に薬物が適用される、請求項6に記載の医薬組成物。
- 外科的介入がヒトに行われる、請求項1〜7のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04010013A EP1591118A1 (en) | 2004-04-27 | 2004-04-27 | Use of melatonin in preventing postoperative complications |
EP04010013.3 | 2004-04-27 | ||
PCT/EP2005/004463 WO2005102319A2 (en) | 2004-04-27 | 2005-04-26 | Use of melatonin in preventing postoperative complications |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007534718A JP2007534718A (ja) | 2007-11-29 |
JP5032981B2 true JP5032981B2 (ja) | 2012-09-26 |
Family
ID=34924759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509957A Expired - Fee Related JP5032981B2 (ja) | 2004-04-27 | 2005-04-26 | メラトニン、および術後合併症の防止におけるその使用 |
Country Status (9)
Country | Link |
---|---|
US (4) | US20080287520A1 (ja) |
EP (3) | EP1591118A1 (ja) |
JP (1) | JP5032981B2 (ja) |
AT (1) | ATE517620T1 (ja) |
CA (1) | CA2564161C (ja) |
DK (1) | DK1744746T3 (ja) |
ES (1) | ES2370499T3 (ja) |
HK (1) | HK1102552A1 (ja) |
WO (1) | WO2005102319A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10420798B2 (en) | 2014-12-31 | 2019-09-24 | Taiwan Mitochondrion Applied Technology Co., Ltd | Method for treating lung injury and/or diseases related to lung injury |
RU2746366C1 (ru) * | 2020-03-18 | 2021-04-12 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) | Способ антибиотикопрофилактики в периоперационном периоде послеоперационных гнойно-воспалительных осложнений |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9403935D0 (en) | 1994-03-01 | 1994-04-20 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
US5519047A (en) * | 1994-04-20 | 1996-05-21 | University Of Utah Research Foundation | Immunomodulatory activity of exogenous melatonin following traumatic injury |
US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
AU710527B2 (en) | 1995-02-23 | 1999-09-23 | Novartis Nutrition Ag | Amino acid compositions and use thereof in clinical nutrition |
GB9510037D0 (en) | 1995-05-18 | 1995-07-12 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
US5700828A (en) * | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
US6013273A (en) * | 1997-01-27 | 2000-01-11 | Novartis Nutrition Ag | Treatment of endotoxic shock |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
AU4501799A (en) | 1998-05-29 | 1999-12-20 | Novartis Nutrition Ag | A new use for glycine |
CA2361575A1 (en) * | 1999-02-05 | 2000-08-10 | Nitrosystems, Inc. | L-arginine based formulations for treating diseases and methods of using same |
AU3913800A (en) * | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
US6552064B2 (en) * | 2000-09-19 | 2003-04-22 | University Of Iowa Research Foundation | Use of melatonin for induction of general anesthesia |
-
2004
- 2004-04-27 EP EP04010013A patent/EP1591118A1/en not_active Withdrawn
-
2005
- 2005-04-26 AT AT05736872T patent/ATE517620T1/de active
- 2005-04-26 US US11/568,371 patent/US20080287520A1/en not_active Abandoned
- 2005-04-26 DK DK05736872.2T patent/DK1744746T3/da active
- 2005-04-26 JP JP2007509957A patent/JP5032981B2/ja not_active Expired - Fee Related
- 2005-04-26 EP EP05736872A patent/EP1744746B1/en not_active Not-in-force
- 2005-04-26 EP EP10011485A patent/EP2316451A1/en not_active Withdrawn
- 2005-04-26 WO PCT/EP2005/004463 patent/WO2005102319A2/en active Application Filing
- 2005-04-26 ES ES05736872T patent/ES2370499T3/es active Active
- 2005-04-26 CA CA2564161A patent/CA2564161C/en not_active Expired - Fee Related
-
2007
- 2007-06-29 HK HK07107002.4A patent/HK1102552A1/xx not_active IP Right Cessation
-
2011
- 2011-08-12 US US13/209,095 patent/US20120178787A1/en not_active Abandoned
-
2014
- 2014-03-10 US US14/203,034 patent/US20140249198A1/en not_active Abandoned
-
2016
- 2016-05-13 US US15/153,819 patent/US20170079953A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1744746B1 (en) | 2011-07-27 |
EP1591118A1 (en) | 2005-11-02 |
ES2370499T3 (es) | 2011-12-19 |
US20080287520A1 (en) | 2008-11-20 |
US20140249198A1 (en) | 2014-09-04 |
WO2005102319A2 (en) | 2005-11-03 |
US20120178787A1 (en) | 2012-07-12 |
US20170079953A1 (en) | 2017-03-23 |
EP2316451A1 (en) | 2011-05-04 |
WO2005102319A3 (en) | 2006-02-23 |
HK1102552A1 (en) | 2007-11-30 |
CA2564161A1 (en) | 2005-11-03 |
EP1744746A2 (en) | 2007-01-24 |
JP2007534718A (ja) | 2007-11-29 |
CA2564161C (en) | 2013-06-25 |
DK1744746T3 (da) | 2011-11-21 |
ATE517620T1 (de) | 2011-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2215618T3 (es) | Compuestos de piridoxina en el tratamiento de patologias cardiovasculares. | |
Paran et al. | Octreotide for treatment of postoperative alimentary tract fistulas | |
US7094797B2 (en) | Organ fibrosis inhibitor | |
Sigurdsson | Intensive care management of acute pancreatitis | |
US20170079953A1 (en) | Melatonin and its use in preventing postoperative complications | |
WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
US20040198841A1 (en) | Use of thiol-based compositions in ameliorating mucosal injury | |
CN112384197A (zh) | 治疗与缺氧相关的组织损伤的给药方案 | |
JP4370054B2 (ja) | 腸粘膜傷害の予防及び治療剤 | |
US20100222371A1 (en) | Prevention of surgical adhesions | |
ES2425398T3 (es) | Antagonistas de receptor de colecistocinina-1 (CCK1) en el tratamiento de trastornos gastrointestinales y relacionados | |
US20220241386A1 (en) | Micronutrient combination to reduce blood pressure | |
RU2703735C1 (ru) | Фармацевтическая композиция, содержащая DHMEQ или его аналоги | |
RU2294204C1 (ru) | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки | |
US20230052601A1 (en) | Halo active aromatic sulfonamide pharmaceutical compositions for internal use | |
RU2577302C2 (ru) | Терапевтическое средство против желудочно-кишечного заболевания | |
US20230225385A1 (en) | Micronutrient combination to reduce blood pressure | |
WO2023027570A1 (es) | Composiciones y métodos para prevenir o reducir el riesgo del síndrome metabólico | |
WO1994028884A1 (en) | Zinc monoglycerolate complex for anti-rejection treatment of the human or animal body | |
RU2039557C1 (ru) | Способ лечения гнойно-воспалительных заболеваний брюшной полости | |
CN117241795A (zh) | 治疗脓毒症的硝唑尼特 | |
RU2196577C2 (ru) | Способ лечения перитонита | |
CA2314818C (en) | Compositions of matter containing l-glutamine and pyridoxal-alpha-ketoglutarate | |
JP2004143149A (ja) | 膵疾患の予防及び/又は治療のための医薬 | |
WO2016165770A1 (en) | 4-phenylbutyric acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120515 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120607 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120629 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5032981 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |